May 09, 2023 / 09:20PM GMT
Jason Matthew Gerberry - BofA Securities, Research Division - MD in US Equity Research
All right, everybody. We're going to get going with our next company presenter here at the BofA Annual Healthcare Conference. My name is Jason Gerberry, I'm one of the biopharma analysts. Pleased to be introducing Intra-Cellular Therapies, Intra-Cellular Therapeutics, and Mark Neumann, Chief Commercial Officer. So Mark, first, thanks for joining us. And I think you have a brief prepared remarks, and then we'll jump into Q&A.
Mark Neumann - Intra-Cellular Therapies, Inc. - EVP & Chief Commercial Officer
Yes. Thank you. Thanks for the invitation, and we're really pleased to be here to be able to share the progress that we're making at ITCI. But before we start, I'll be making some forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Our actual results may differ, so I refer you to our website and to our SEC filings for updates on the company.
Intra-Cellular Therapies Inc at Bank of America Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot